{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:41:39Z","timestamp":1789188099392,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 111-2113-M-A49-018"],"award-info":[{"award-number":["NSTC 111-2113-M-A49-018"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2321-B-A49-005"],"award-info":[{"award-number":["NSTC 112-2321-B-A49-005"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2024.e24333","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T12:53:28Z","timestamp":1704891208000},"page":"e24333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetic analysis of placental transfer of ritonavir as a component of paxlovid using microdialysis in pregnant rats"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5129-8562","authenticated-orcid":false,"given":"Chung-Kai","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Hsin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muh-Hwa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9007-2547","authenticated-orcid":false,"given":"Tung-Hu","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e24333_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","article-title":"Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents","volume":"35","author":"Hsu","year":"1998","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.heliyon.2024.e24333_bib2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/bcp.12668","article-title":"Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies","volume":"80","author":"Greenblatt","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e24333_bib3","first-page":"23","article-title":"The mechanism-based inactivation of CYP3A4 by ritonavir: what mechanism?","author":"Loos","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e24333_bib4","first-page":"38","article-title":"Safety and efficacy of lopinavir\/ritonavir during pregnancy: a systematic review","volume":"15","author":"Pasley","year":"2013","journal-title":"AIDS Rev."},{"key":"10.1016\/j.heliyon.2024.e24333_bib5","first-page":"101","article-title":"Drug interactions with cobicistat- or ritonavir-boosted elvitegravir","volume":"18","author":"Nguyen","year":"2016","journal-title":"AIDS Rev."},{"key":"10.1016\/j.heliyon.2024.e24333_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1358\/dot.2008.44.2.1137107","article-title":"Atazanavir\/ritonavir: a review of its use in HIV therapy","volume":"44","author":"von Hentig","year":"2008","journal-title":"Drugs Today"},{"key":"10.1016\/j.heliyon.2024.e24333_bib7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40265-022-01692-5","article-title":"Nirmatrelvir plus ritonavir: first approval","volume":"82","author":"Lamb","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e24333_bib8","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1093\/jac\/dkaa261","article-title":"Pharmacokinetics of lopinavir\/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients","volume":"75","author":"L\u00ea","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.heliyon.2024.e24333_bib9","series-title":"In LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"10.1016\/j.heliyon.2024.e24333_bib10","unstructured":"USFDA. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults. Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-antiviral-treatment-covid-19-adults (accessed on November 2nd, 2023).."},{"key":"10.1016\/j.heliyon.2024.e24333_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.clpt.2004.02.008","article-title":"Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers","volume":"76","author":"Ding","year":"2004","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e24333_bib12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ajog.2006.01.017","article-title":"Placental transfer of lopinavir\/ritonavir in the ex vivo human cotyledon perfusion model","volume":"195","author":"Gavard","year":"2006","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.heliyon.2024.e24333_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.44141","article-title":"Analysis of clinical outcomes of pregnant patients treated with nirmatrelvir and ritonavir for acute SARS-CoV-2 infection","volume":"5","author":"Garneau","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.heliyon.2024.e24333_bib14","unstructured":"EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19: rolling review starts in parallel. Available online: https:\/\/www.ema.europa.eu\/en\/news\/ema-issues-advice-use-paxlovid-pf-07321332-ritonavir-treatment-covid-19-rolling-review-starts (accessed on 16 June)."},{"key":"10.1016\/j.heliyon.2024.e24333_bib15","article-title":"Chemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant rats","volume":"7","author":"Lin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e24333_bib16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1124\/dmd.120.000088","article-title":"Preclinical transplacental transfer and pharmacokinetics of fipronil in rats","volume":"48","author":"Chang","year":"2020","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.heliyon.2024.e24333_bib17","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1021\/acsptsci.1c00142","article-title":"Blood-placental barrier transfers and pharmacokinetics of unbound morphine in pregnant rats with multiple microdialysis systems","volume":"4","author":"Lin","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.heliyon.2024.e24333_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112489","article-title":"Trans-placental transfer of nicotine: modulation by organic cation transporters","volume":"145","author":"Lin","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e24333_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104095","article-title":"Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats","volume":"81","author":"Yang","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.heliyon.2024.e24333_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115623","article-title":"Pharmacokinetics and transplacental transfer of codeine and codeine metabolites from Papaver somniferum L","volume":"298","author":"Chen","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.heliyon.2024.e24333_bib21","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0169-409X(00)00110-1","article-title":"Blood microdialysis in pharmacokinetic and drug metabolism studies","volume":"45","author":"Verbeeck","year":"2000","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.heliyon.2024.e24333_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1046\/j.1440-1681.2003.03789.x","article-title":"Intracerebral microdialysis: 30 years as a tool for the neuroscientist","volume":"30","author":"Bourne","year":"2003","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.heliyon.2024.e24333_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jchromb.2003.08.036","article-title":"Assaying protein unbound drugs using microdialysis techniques","volume":"797","author":"Tsai","year":"2003","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.heliyon.2024.e24333_bib24","first-page":"573","article-title":"Chapter 6.5 Assaying protein-unbound drugs using microdialysis techniques","volume":"vol. 16","author":"Tsai","year":"2006"},{"key":"10.1016\/j.heliyon.2024.e24333_bib25","first-page":"589","article-title":"Chapter 6.6 Microdialysis for characterization of PK\/PD relationships","volume":"vol. 16","author":"Hammarlund-Udenaes","year":"2006"},{"key":"10.1016\/j.heliyon.2024.e24333_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41598-022-26944-y","article-title":"Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations","volume":"13","author":"Imam","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e24333_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115796","article-title":"Simultaneous quantification of nirmatrelvir\/ritonavir in human serum by LC-HRMS","volume":"237","author":"Zhao","year":"2024","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.heliyon.2024.e24333_bib28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/bmc.3021","article-title":"Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS\/MS","volume":"28","author":"Hendrikx","year":"2014","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.heliyon.2024.e24333_bib29","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1016\/j.jchromb.2011.08.034","article-title":"A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry","volume":"879","author":"Hendrikx","year":"2011","journal-title":"J. Chromatogr., B: Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.heliyon.2024.e24333_bib30","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1038\/s41598-023-32904-x","article-title":"Simultaneous green TLC determination of nirmatrelvir and ritonavir in the pharmaceutical dosage form and spiked human plasma","volume":"13","author":"Imam","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.heliyon.2024.e24333_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13065-023-01030-0","article-title":"Higher sensitive selective spectrofluorometric determination of ritonavir in the presence of nirmatrelvir: application to new FDA approved co-packaged COVID-19 pharmaceutical dosage and spiked human plasma","volume":"17","author":"Imam","year":"2023","journal-title":"BMC Chem."},{"key":"10.1016\/j.heliyon.2024.e24333_bib32","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cll.2016.07.001","article-title":"Liquid chromatography-tandem mass spectrometry: an emerging Technology in the toxicology laboratory","volume":"36","author":"Zhang","year":"2016","journal-title":"Clin. Lab. Med."},{"key":"10.1016\/j.heliyon.2024.e24333_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0378-4347(92)80526-V","article-title":"Systematic toxicological analysis of drugs and their metabolites by gas chromatography-mass spectrometry","volume":"580","author":"Maurer","year":"1992","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.heliyon.2024.e24333_bib34","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jpha.2015.05.001","article-title":"Thermal stability and hydration behavior of ritonavir sulfate: a vibrational spectroscopic approach","volume":"5","author":"Gambhir","year":"2015","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.heliyon.2024.e24333_bib35","unstructured":"USFDA. Bioanalytical Method Validation Guidance for Industry. Available online: https:\/\/www.fda.gov\/files\/drugs\/published\/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf (accessed on November 15th, 2021).."},{"key":"10.1016\/j.heliyon.2024.e24333_bib36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0021-9673(99)00854-7","article-title":"Measurement and pharmacokinetics of unbound 20(S)-camptothecin in rat blood and brain by microdialysis coupled to microbore liquid chromatography with fluorescence detection","volume":"870","author":"Tsai","year":"2000","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.heliyon.2024.e24333_bib37","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01117450","article-title":"Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations","volume":"6","author":"Yamaoka","year":"1978","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"10.1016\/j.heliyon.2024.e24333_bib38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.heliyon.2024.e24333_bib39","first-page":"9","volume":"64","year":"2022","journal-title":"Med. Lett. Drugs Ther."},{"key":"10.1016\/j.heliyon.2024.e24333_bib40","series-title":"Infectious Diseases","first-page":"1434","article-title":"Chapter 145 - antiretroviral agents","author":"Kubin","year":"2010"},{"key":"10.1016\/j.heliyon.2024.e24333_bib41","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/antibiotics11020220","article-title":"Oral nirmatrelvir\/ritonavir therapy for COVID-19: the dawn in the dark?","volume":"11","author":"Hung","year":"2022","journal-title":"Antibiotics"},{"key":"10.1016\/j.heliyon.2024.e24333_bib42","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00228-013-1530-8","article-title":"Concentration effect relationship of CYP3A inhibition by ritonavir in humans","volume":"69","author":"Eichbaum","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e24333_bib43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.2603","article-title":"Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir","volume":"112","author":"Singh","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.heliyon.2024.e24333_bib44","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/1061186X.2012.716847","article-title":"Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure","volume":"20","author":"Staud","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.heliyon.2024.e24333_bib45","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1517\/17425255.2013.741589","article-title":"Species differences in drug transporters and implications for translating preclinical findings to humans","volume":"9","author":"Chu","year":"2013","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e24333_bib46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.reprotox.2018.05.008","article-title":"Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: effect on transplacental disposition in rats","volume":"79","author":"Cerveny","year":"2018","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.heliyon.2024.e24333_bib47","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1515\/jpme.1982.10.2.119","article-title":"Ritodrine concentrations in maternal and fetal serum and amniotic fluid","volume":"10","author":"van Lierde","year":"1982","journal-title":"J. Perinat. Med."},{"key":"10.1016\/j.heliyon.2024.e24333_bib48","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.pnpbp.2017.06.030","article-title":"Pregnancy exposure to citalopram - therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood","volume":"79","author":"Paulzen","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.heliyon.2024.e24333_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2017.01.019","article-title":"Sertraline in pregnancy - therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood","volume":"212","author":"Paulzen","year":"2017","journal-title":"J. Affect. Disord."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024003645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024003645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:37:02Z","timestamp":1783931822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024003645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844024003645"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24333","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic analysis of placental transfer of ritonavir as a component of paxlovid using microdialysis in pregnant rats","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e24333"}}